Five midcap stocks that investors should have on their radar today!

Five mid cap names

by 5paisa Research Team Last Updated: 2022-05-25T11:07:42+05:30

Check out the midcap companies making headlines in the morning trade session.    

Among the midcap companies, Ipca Laboratories, Bayer Cropscience, Aster DM Healthcare, Minda Industries, and Metropolis Healthcare are among the stocks in the news on Wednesday. Let us see why!    

Ipca Laboratories: The company is in the news for its Q4 & FY22 results which were quite mediocre. It posted a decrease of 14% in Q4 consolidated net profit of Rs 140.8 crore on a YoY basis. However, the topline was up by 15.65% YoY to Rs 485.5 crore. The consolidated net profit for the year ended March 31, 2022, was Rs 911 crore, down 20.7% against the same day last year. At 10:00 am on Wednesday, the stock was trading at Rs 957.80, slightly up 0.23% or Rs 2.20 per share.    

Bayer Cropscience: The stock has hit the list of top gainers today as it posted healthy growth in financials. In Q4FY22, revenue grew by 31.29% YoY to Rs 963.3 crore from Rs 733.7 crore in Q4FY21. On a sequential basis, the top-line was down by 2.7%. PBIDT (Ex OI) was reported at Rs 200.7 crore, up by 142.68% YoY and its margin was reported at 20.83%, expanding by 956 basis points YoY. PAT was reported at Rs 152.7 crore, up by 146.69% YoY. Simon-Thorsten Wiebusch, Executive Director, commented on Q4 results, “New product launches such as Vayego and Dekalb 9208 and overall strong crop sentiments were key drivers for our sales growth in Q4. This has been achieved overcoming some supply constraints faced during the quarter and partially offsetting inflationary pressure with price increases.” At 10 am on Wednesday, the stock was trading at Rs 4,980.55, up by nearly 5.13% or Rs 243 per share.    

Aster DM Healthcare: One of the leading midcap S&P 500 hospital chain companies reported robust Q4 and FY22 results that have sent the stock flying. For Q4, the revenues and net profit were up by 14% and 110% YoY to Rs 2,728 crore and Rs 246 crore, respectively. The management said that the company witnessed significant improvement in facility utilization. Its business in India is growing fast as it is continuously adding beds quarter after quarter. At the time of writing, shares of the company were trading at Rs 191.75, up by 11.03%, thus making it one of the top gainers of the day in group A of the BSE.  

Minda Industries: The stock is in the buzz for many reasons. The company in its board meeting has given a green signal for raising funds through debt securities up to Rs 1,000 crore in one or more tranches. It has also recommended a final dividend of Rs 1 on the face value of Rs 2 per equity share. For the whole year, the total dividend issued is Rs 1.5 on the face value of Rs 2 per equity share. It has also posted Q4 & FY22 results. For Q4, revenue and PAT were up by 7.9% and down by 11%, respectively. For FY22, the topline and bottomline jumped 30.4% and 54.9% respectively. At 10 am on Wednesday, the stock was trading at Rs 878.50, up 5.20% or Rs 43.40 per share.    

Metropolis Healthcare: Metropolis Healthcare is one of the leading diagnostics companies in India, by revenue. In Q4FY22, revenue grew by 4.86% YoY to Rs 305.9 crore from Rs 291.73 crore in Q4FY21. On a sequential basis, the top-line was up by 4.38%. PBIDT (Ex OI) was reported at Rs 74.85 crore, down by 22.35% YoY and its margin was reported at 24.47%, contracting by 857 basis points YoY. PAT was reported at Rs 40.15 crore, down by 34.53% from Rs 61.32 crore in the same quarter for the previous fiscal year. The PAT margin stood at 13.12% in Q4FY22 contracting from 21.02% in Q4FY21. At the time of writing, the stock was trading at Rs 1,672, down 1% or Rs 16.5 per share. 

Start Investing in 5 mins*

Get Benefits worth 2100* | Rs. 20 Flat Per Order | 0% Brokerage

About the Author

Our research team is composed of some highly qualified research professionals, their expertise range across sectors.


Investment/Trading in securities Market is subject to market risk, past performance is not a guarantee of future performance. The risk of loss in trading and investment in Securities markets including Equites and Derivatives can be substantial.

Open Free Demat Account

& get benefits worth 2100*

Resend OTP
Please Enter OTP
  • Have Promo code?
  • Use code ACT2100
Enter Promo code
Account belongs to

By proceeding, you agree to the T&C.

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number